Suprax returning to market
Executive Summary
The cephalosporin antibiotic Suprax (cefixime) is returning to the market after a one-year absence. The Bombay-based generic drug firm Lupin is taking over the product from Wyeth, which discontinued production in 2002 (1"The Pink Sheet" Dec. 2, 2002, In Brief); stock was exhausted in 2003. Lupin expects to have the oral suspension formulation available in April following the approval of its ANDA (65-129) on Feb. 23. The company is not projecting availability for the tablets (ANDA 65-130), approved Feb. 12. Suprax will be Lupin's first U.S. product and will be detailed by 45 sales reps calling primarily on pediatricians. Sales of Suprax during Wyeth's last year of production were approximately $50 mil...
You may also be interested in...
Wyeth discontinues Suprax
Wyeth will continue to sell oral antimicrobial Suprax (cefixime) suspension through March or until company's supply is depleted, following decision to discontinue the product. Cefixime lost patent protection on Nov. 10; Wyeth said it had always intended to cease marketing the drug once it lost exclusivity...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.